- cafead Nov 07, 2022 at 10:52: AM
via Inhibikase Therapeutics has been left stumped and its stock bruised after the FDA unexpectedly placed a clinical hold on its midstage Parkinson’s disease drug.
The therapy, an Abelson tyrosine kinase inhibitor called IkT-148009, was undergoing a phase 2 trial for Parkinson’s.
article source
The therapy, an Abelson tyrosine kinase inhibitor called IkT-148009, was undergoing a phase 2 trial for Parkinson’s.
article source